Ann: Positive in vitro data for CHM 1301 CAR NK cells-supplement, page-5

The value this could mean to CHM is impressive…


I think the team provided a great update in todays webinar and near term potential for CHM1101 and CHM1301

I have a lot of respect and trust in this team and will see how that plays out over the longer term.
CHM1101 is already showing better than SOC potential in 4th line treatments. Now it’s moving into 2nd line and potentially a more targeted patient set if the analysis of the data can identify this

CHM1301 then enhancing this promising treatment and broadening it’s targeted cancer types to now include two of the most devastating of cancer being GBM and pancreatic.


I’ll have to review the current research support agreement but I think Jennifer was eluding to the fact the CHM1301 research will be cost effective…curious if this leads to another investigator led trial with case western footing the phase1a trial they will be aiming for. Would be great for cash preservation. To have the amount of activity and trials with such limited funding a real testament to the teams network and the potential of the science. Prominent scientists and institutions are excited about the research and potential impact on patients lives and are putting their money behind the progression of CHM’s assets. I’m following these experts on backing CHM.

talking about potential fast track approval and strengthening IP value with these recent developments


oh yeah don’t forget about the CDH17 about to be in clinic and then they roll this into the CHM0201 and hopefully enhance again and broaden targeted cancers

to the recent deals point discussed there was a recent one with Takeda at around $1.3b USD for a colorectal treatment

next few years will be very interesting and let’s hope profitable